How to Help Your Patients Find Carboplatin in Stock: A Provider's Guide

For oncology providers, the carboplatin shortage that began in April 2023 has added a layer of logistical complexity to an already demanding clinical environment. Beyond clinical decision-making, your team is often the patient's first line of support in locating the drug they need. This guide provides practical, actionable strategies your practice or institution can use to help patients find carboplatin in stock and minimize disruptions to their treatment schedules.

Step 1: Proactive Inventory Communication with Your Pharmacy Team

The most effective intervention is early awareness. Establish a weekly check-in with your oncology pharmacy team to review current carboplatin inventory, upcoming allocation releases, and the schedule of patients requiring carboplatin in the next 2–3 weeks. If your supply projection shows a gap, you have time to act.

Review your GPO account's projected weekly allocations every Monday

Cross-reference with the ASHP shortage database for manufacturer updates

Create a running list of patients on carboplatin-containing regimens with their next cycle dates

Step 2: Establish a Shortage Protocol Before You Need It

Every oncology practice should have a documented carboplatin shortage protocol that defines:

The threshold at which rationing decisions begin (e.g., supply falls below 3 weeks' anticipated need)

The clinical committee responsible for allocation decisions

Criteria for patient prioritization (curative vs. palliative intent, stage, cycle point in regimen)

Conservation tactics: dose rounding, cycle extension by 1–2 weeks, vial-sharing on same-day infusions

Referral pathways to NCI-designated centers or larger institutions with greater supply access

Step 3: Source from Multiple Distributors

During shortage periods, relying on a single distributor is risky. Your pharmacy team should actively check multiple wholesalers (e.g., McKesson, Cardinal Health, AmerisourceBergen) for carboplatin availability across all four vial sizes (50 mg, 150 mg, 450 mg, 600 mg). If one size is unavailable, another size combination may achieve the required dose.

Step 4: Use medfinder to Extend Your Search

For patients who need to find an infusion center or specialty pharmacy with carboplatin availability, medfinder for providers is a useful resource. medfinder calls pharmacies and infusion centers near your patient to find out which ones can fill their carboplatin prescription. This is particularly valuable for patients who live in areas with limited oncology infrastructure or for community practices without the network resources of large academic centers.

Step 5: Facilitate Referral to Larger Centers When Needed

NCI-designated comprehensive cancer centers and academic medical centers often have better supply access through institutional contracts and GPO priority allocations. If your practice cannot secure carboplatin for a patient requiring curative-intent treatment, a timely referral to a larger center — even temporarily for one or two cycles — may be the best option. Document this in the care plan and maintain communication so the patient can transition back to your practice once supply is secured.

Step 6: Communicate Clearly with Your Patients

Patients dealing with a cancer diagnosis are already under significant psychological stress. When carboplatin supply constraints affect their treatment schedule, how you communicate matters. Best practices include:

Explain the national shortage context so patients understand this is not a clinic-specific issue

Be specific about what is being done to secure their supply and provide realistic timelines

Explain the clinical rationale for any dose modification or cycle adjustment clearly and reassuringly

Provide written resources — including how to use services like medfinder — so patients feel empowered to help themselves when appropriate

Step 7: Document Shortage-Related Treatment Modifications

Always document in the patient's chart when a treatment modification was made due to drug shortage rather than clinical indication. This protects you clinically, supports the patient's oncologic history, and contributes to real-world evidence about shortage impact. See also our article on what providers need to know about the 2026 carboplatin shortage for a full clinical overview.